Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study

Background Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data on the early combined use of antivirals and monoclonal antibodies in this population are scarce.Research design and methods We performed an observational, prospective study, enrolling immunocompr...

Full description

Saved in:
Bibliographic Details
Main Authors: I. Gentile, G. Viceconte, F. Cuccurullo, D. Pietroluongo, A. D’Agostino, M. Silvitelli, S. Mercinelli, R. Scotto, F. Grimaldi, S. Palmieri, A. Gravetti, F. Trastulli, M. Moccia, A. R. Buonomo
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Annals of Medicine
Subjects:
COVID-19
immunocompromised
combination
sotrovimab
nirmatrelvir
remdesivir
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2024.2439541
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2024.2439541

Similar Items